Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin 850 mg Clear all
Withdrawn Phase 1Phase 2 Interventional

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

NCT02143050
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Metformin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Genomic Outcomes of Metformin

NCT02986659
View directory record Official record
Conditions
Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
Interventions
Metformin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506
View directory record Official record
Conditions
Breast Cancer
Interventions
Metformin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

NCT04865835
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, SEP-363856, metformin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Oakland Park, Florida • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

NCT01719614
View directory record Official record
Conditions
Healthy Participants
Interventions
Metformin, Rilpivirine
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin for Rising PSA Remote Trial

NCT02376166
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo

NCT02682121
View directory record Official record
Conditions
Prediabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Genetics on Metformin Pharmacokinetics

NCT00187798
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin HCl
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

NCT02633488
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Sensitivity
Interventions
Placebos, metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

NCT01929863
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463774
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: Canagliflozin tablet, Treatment A: Metformin IR tablets, Treatment B: Canagliflozin/metformin fixed dose combination tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 28, 2026, 6:11 PM EDT
Not listed Phase 2 Interventional

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

NCT02437812
View directory record Official record
Conditions
Epithelial Ovarian Carcinoma
Interventions
Metformin, Paclitaxel, Carboplatin
Drug
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 28, 2026, 6:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

NCT06030622
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

NCT01813929
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 28, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 28, 2026, 6:11 PM EDT
Terminated Not applicable Interventional Results available

Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery

NCT00984490
View directory record Official record
Conditions
Breast Cancer
Interventions
metformin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects

NCT00187681
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Francsico, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 28, 2026, 6:11 PM EDT
Completed Early Phase 1 Interventional

Metformin for the Treatment of Endometrial Hyperplasia

NCT01685762
View directory record Official record
Conditions
Endometrial Hyperplasia, Endometrial Hyperplasia Without Atypia
Interventions
Metformin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Southern Pines, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 28, 2026, 6:11 PM EDT
Active, not recruiting Phase 1 Interventional

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

NCT03889795
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Advanced Solid Tumor
Interventions
Metformin, Simvastatin, Digoxin
Drug
Lead sponsor
Danae Hamouda, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 28, 2026, 6:11 PM EDT